BJMO - volume 11, issue 7, november 2017
W. Lybaert MD
In this article, the most important new studies presented at ESMO 2017 in Madrid in early (EBC) and metastatic breast cancer (MBC) are summarised. In EBC, 5 topics are highlighted: integration of PI3K and CDK4/6 inhibition in the neoadjuvant treatment of oestrogen receptor positive (ER+) EBC, dual endocrine blockade as adjuvant treatment in ER+ EBC, escalated adjuvant treatment in human epidermal growth factor receptor positive (HER2+) EBC and small tumours that can also show an aggressive course. In MBC, 4 topics are discussed: predicting immunogenicity in MBC, abscopal effect in MBC, confirmed benefit of PARP inhibitors in BRCA mutated MBC and CDK4/6 inhibition in first-line MBC.
(BELG J ONCOL 2017;11(7):309–314)
Read moreBJMO - volume 11, issue 3, may 2017
W. Lybaert MD, M. Simoens , Wim Demey MD, F. van Fraeyenhove MD, T. Vandamme MD, PhD, L. De Backer , M. Peeters MD, PhD
Barcelona, 8-10 March 2017.
(BELG J MED ONCOL 2017;11(3):129–133)
Read moreBJMO - 2017, issue 3, february 2017
L. Jongen , P. Neven MD, PhD, A. Lintermans , K. Van Asten MSc, C. Blomme , D. Lambrechts PhD, A. Poppe , H. Wildiers MD, PhD, A.S. Dieudonné , J. Decloedt MD, P. Berteloot , D. Verhoeven MD, PhD, M. Joerger , P. Vuylsteke MD, W. Wynendaele MD, PhD, M. Casteels , Sabine Van Huffel , W. Lybaert MD, J. Van Ginderachter , R. Paridaens , I. Vergote MD, PhD, V. Dezentjé , B. Van Calster PhD, H-J. Guchelaar
BJMO - 2017, issue 3, february 2017
W. Lybaert MD, T. Vandamme MD, PhD, M. Simoens , I. Dero MD, Wim Demey MD, T. Rondou , A. Cuypers , P. Abrams , C. Mattelaer , A. Driessen MD, PhD, B. Op de Beeck , O. D’Archambeau , G. Roeyen MD, PhD, L. De Backer , M. Peeters MD, PhD, NET specialists NETwerk Steering Committee
BJMO - 2017, issue 3, february 2017
B. De Laere PhD, P. Van Oyen , C. Ghysel , P. Ost MD, PhD, Wim Demey MD, L. Hoekx MD, D. Schrijvers MD, PhD, B. Brouwers MD, PhD, W. Lybaert MD, E. Everaert , J. Ampe , P. Van Kerckhove , D. De Maeseneer MD, M. Strijbos MD, PhD, A. Bols MD, PhD, K. Fransis , S. Oeyen , V. Van Dam , A. Brouwer , G. Van Den Eynden MD, PhD, A. Rutten MD, J. Vandebroek , S. Van Laere PhD, L. Dirix MD
BJMO - 2017, issue 3, february 2017
W. Lybaert MD, T. Vandamme MD, PhD, M. Simoens , P. Abrams , Wim Demey MD, T. Rondou , M. Ulenaers MD, G. Vanhoutte , M. Peeters MD, PhD, NET specialists NETwerk Steering Committee
BJMO - volume 10, issue 2, april 2016
B. Dekeyser MD, M. Haagdorens MD, I. Deleu MD, E. Van Hul MD, E. Beerens MD, D. Van der Planken MD, K. Hendrickx MD, L. Verstraeten MD, Y. Geussens MD, W. Lybaert MD
A 54-year old man presented with a new-onset headache, phonophobia, tinnitus, blurred vision, and nausea. Further imaging and histological examination confirmed the diagnosis of an olfactory neuroblastoma. Olfactory neuroblastoma or esthesioneuroblastoma is a rare type of cancer, originating from the basal stem cells of the olfactory epithelium in the nasal cavity. The patient received a maximal possible surgical resection of the tumour, followed by adjuvant chemo-irradiation. Given the absence of neck metastases, no prophylactic treatment of the neck was done. Recent studies state that standard treatment of esthe-sioneuroblastoma consists of surgical resection, followed by local radiotherapy. Adjuvant chemotherapy is recommended for the locally advanced tumours. As for the treatment of the neck, current consensus is to perform salvage therapy when neck metastases are present.
(BELG J MED ONCOL 2016;10(2):69–72)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
